Alpha Tau Medical Ltd. announced on August 31, 2026, that it has completed patient enrollment in its multicenter IMPACT pilot study evaluating Alpha DaRT for newly diagnosed unresectable pancreatic cancer. The trial expanded enrollment three times from an initial target of 12 to a total of 48 treated patients across the United States, Canada, and Israel. Initial data is targeted for release in early 2027 to inform the design of a planned pivotal study. Alpha Tau Medical Ltd. operates in the oncology therapeutics industry, focusing on the research and development of alpha-radiation cancer therapy.

Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT therapy in combination with pembrolizumab for treating head and neck squamous cell carcinoma. The study met its pre-specified success criterion, demonstrating a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients. Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company that develops Alpha DaRT technology for the treatment of solid tumors.

Alpha Tau Medical Ltd. announced the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center in Arizona. The company is a developer of photo-immunotherapy technology for own-purpose use in oncology.

On June 23, 2026, Alpha Tau Medical Ltd. announced the successful treatment of its first recurrent glioblastoma patient outside the United States using Alpha DaRT therapy at Hadassah University Medical Center in Israel. The company operates in the medical device industry and develops cancer treatment technologies.

On June 11, 2026, Alpha Tau Medical Ltd. announced it received FDA clearance to complete enrollment in the REGAIN Recurrent Glioblastoma Trial and to add two additional U.S. clinical sites. Early interim results from the trial demonstrated 100% local disease control. The company operates in the medical device industry, developing oncology treatments.